Preclinical Targeted α- and β<sup>−</sup>-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Janik Puttemans, Yana Dekempeneer, Jos L. Eersels, Heleen Hanssens, Pieterjan Debie, Marleen Keyaerts, Albert D. Windhorst, Frank van der Aa, Quentin Lecocq, Karine Breckpot, Alfred Morgenstern, Frank Bruchertseifer, Tony Lahoutte, Nick Devoogdt, Matthias D’Huyvetter
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI AG 2020-04-01
Saila:Cancers
Gaiak:
single-domain antibody fragment
targeted radionuclide therapy
brain metastasis
HER2
Sarrera elektronikoa:https://www.mdpi.com/2072-6694/12/4/1017
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak